Oncolix, Inc. (Oncolix) is a clinical-stage biotechnology company
We are developing Prolanta™,a targeted therapeutic protein for the treatment of ovarian, breast and other cancers. The Company has a US FDA-cleared IND to commence human testing of Prolanta™ in our first indication, the treatment of ovarian cancer. This clinical trial began in 2016. Preliminary data from the first dosing group (the low dose) of this trial suggest Prolanta is safe with some evidence of efficacy in a patient population that is difficult to treat. Prolanta™ is a prolactin receptor antagonist that has demonstrated significant efficacy in xenograft models through a unique mechanism of action, autophagy (see Our Science). In addition to ovarian cancer, there is strong preclinical evidence Prolanta™ will be effective in breast, prostate and other cancers.
The FDA has also approved the designation of Prolanta™ as an Orphan Drug for the treatment of ovarian cancer, which may allow reduced filing fees, federal tax credits and marketing exclusivity by the FDA.
Market Value: $5,435,404 a/o Sep 08, 2017
Authorized Shares: 500,000,000 a/o Sep 01, 2017
Outstanding Shares: 93,231,633 a/o Sep 01, 2017
Float: 33,311,633 a/o Apr 06, 2017
Shareholders of Record: 101 a/o Apr 06, 2017
Transfer Agent: VStock Transfer LLC
Michael T. Redman – CEO
J. Donals Payne – CFO